New hope for tough liver cancer: Triple-Threat therapy tested
NCT ID NCT06925516
Summary
This study is testing a new combination of three drugs as the first treatment for advanced bile duct cancer that cannot be removed by surgery. The goal is to see if adding two newer drugs (apatinib and adebrelimab) to standard chemotherapy can shrink tumors better and help patients live longer. About 38 patients will receive this combination treatment and be monitored for effectiveness and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.